Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
Inhibition of Diacylglycerol Acyltransferase 2 Versus
Beyond triglyceride synthesis: the dynamic functional roles of
Full article: Patent landscape for discovery of promising
BMS-963272Cas# 1441057-15-3
Diseases, Free Full-Text
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
PDF] MGAT2, a Monoacylglycerol Acyltransferase Expressed in the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
MGAT2 inhibitor decreases liver fibrosis and inflammation in
Metabolomics combined with network pharmacology exploration
The monoacylglycerol acyltransferase pathway contributes to
Frontiers New insights into the role of dietary triglyceride
Frontiers New insights into the role of dietary triglyceride
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic
de
por adulto (o preço varia de acordo com o tamanho do grupo)
